Trial Profile
A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluorine 18 THK 5351 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use; Pharmacokinetics
- 11 Dec 2020 Status changed from recruiting to completed.
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 18 Apr 2017 New trial record